PMID- 32168854
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-3921 (Print)
IS  - 2076-3921 (Electronic)
IS  - 2076-3921 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Mar 11
TI  - Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress 
      Biomarkers in Patients with Type 2 Diabetes Mellitus.
LID - 10.3390/antiox9030233 [doi]
LID - 233
AB  - : Pre-clinical studies suggested potential cardiovascular benefits of dipeptidyl 
      peptidase-4 inhibitors (DPP4i), however, clinical trials showed neither 
      beneficial nor detrimental effects in patients with type 2 diabetes mellitus 
      (T2DM). We examined the effects of DPP4i on several circulating oxidative stress 
      markers in a cohort of 32 T2DM patients (21 males and 11 post-menopausal 
      females), who were already on routine antidiabetic treatment. Propensity score 
      matching was used to adjust demographic and clinical characteristics between 
      patients who received and who did not receive DPP4i. Whole-blood reactive oxygen 
      species (ROS), plasma advanced glycation end products (AGEs), advanced oxidation 
      protein products (AOPP), carbonyl residues, as well as ferric reducing ability of 
      plasma (FRAP) and leukocyte DNA oxidative damage (Fpg sites), were evaluated. 
      With the exception of Fpg sites, that showed a borderline increase in DPP4i users 
      compared to non-users (p = 0.0507), none of the biomarkers measured was affected 
      by DPP4i treatment. An inverse correlation between estimated glomerular 
      filtration rate and AGEs (p < 0.0001) and Fpg sites (p < 0.05) was also observed. 
      This study does not show any major effect of DPP4i on oxidative stress, assessed 
      by several circulating biomarkers of oxidative damage, in propensity 
      score-matched cohorts of T2DM patients.
FAU - Bigagli, Elisabetta
AU  - Bigagli E
AD  - Department of Neurosciences, Psychology, Drug Research and Child Health 
      (NEUROFARBA), section of Pharmacology and Toxicology, University of 
      Florence,50139 Florence, Italy.
FAU - Luceri, Cristina
AU  - Luceri C
AD  - Department of Neurosciences, Psychology, Drug Research and Child Health 
      (NEUROFARBA), section of Pharmacology and Toxicology, University of 
      Florence,50139 Florence, Italy.
FAU - Dicembrini, Ilaria
AU  - Dicembrini I
AD  - Department of Clinical and Experimental Biomedical Sciences, University of 
      Florence and Diabetology Unit, Careggi Hospital,50139 Florence, Italy.
FAU - Tatti, Lorenzo
AU  - Tatti L
AD  - Department of Neurosciences, Psychology, Drug Research and Child Health 
      (NEUROFARBA), section of Pharmacology and Toxicology, University of 
      Florence,50139 Florence, Italy.
FAU - Scavone, Francesca
AU  - Scavone F
AD  - Department of Neurosciences, Psychology, Drug Research and Child Health 
      (NEUROFARBA), section of Pharmacology and Toxicology, University of 
      Florence,50139 Florence, Italy.
FAU - Giovannelli, Lisa
AU  - Giovannelli L
AD  - Department of Neurosciences, Psychology, Drug Research and Child Health 
      (NEUROFARBA), section of Pharmacology and Toxicology, University of 
      Florence,50139 Florence, Italy.
FAU - Mannucci, Edoardo
AU  - Mannucci E
AD  - Department of Clinical and Experimental Biomedical Sciences, University of 
      Florence and Diabetology Unit, Careggi Hospital,50139 Florence, Italy.
FAU - Lodovici, Maura
AU  - Lodovici M
AD  - Department of Neurosciences, Psychology, Drug Research and Child Health 
      (NEUROFARBA), section of Pharmacology and Toxicology, University of 
      Florence,50139 Florence, Italy.
LA  - eng
GR  - 2017.0841/Ente Cassa di Risparmio di Firenze/
PT  - Journal Article
DEP - 20200311
PL  - Switzerland
TA  - Antioxidants (Basel)
JT  - Antioxidants (Basel, Switzerland)
JID - 101668981
PMC - PMC7139569
OTO - NOTNLM
OT  - biomarkers
OT  - dipeptidyl peptidase-4 inhibitors
OT  - oxidative stress
OT  - type 2 diabetes
COIS- I.D has received speaking fees from Astra Zeneca, Bristol Myers Squibb, 
      BoehringerIngelheim, Eli-Lilly, Merck, Novo Nordisk, Sanofi, and Novartis. EM has 
      received speaking fees from from Astra Zeneca, Bristol Myers Squibb, 
      Boehringer-Ingelheim, Eli-Lilly, Merck, Novo Nordisk, Sanofi, and Novartis and 
      research grants from Merck, Novartis, and Takeda. The other authors declare that 
      they have no conflicts of interest.
EDAT- 2020/03/15 06:00
MHDA- 2020/03/15 06:01
PMCR- 2020/03/11
CRDT- 2020/03/15 06:00
PHST- 2020/02/12 00:00 [received]
PHST- 2020/03/04 00:00 [revised]
PHST- 2020/03/09 00:00 [accepted]
PHST- 2020/03/15 06:00 [entrez]
PHST- 2020/03/15 06:00 [pubmed]
PHST- 2020/03/15 06:01 [medline]
PHST- 2020/03/11 00:00 [pmc-release]
AID - antiox9030233 [pii]
AID - antioxidants-09-00233 [pii]
AID - 10.3390/antiox9030233 [doi]
PST - epublish
SO  - Antioxidants (Basel). 2020 Mar 11;9(3):233. doi: 10.3390/antiox9030233.